24th Jul 2019 18:01
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sir Philip Hampton | |||
b) | Position/status | Non-Executive Chairman
| |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.54 | 2,645.103 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr Vindi Banga | |||
b) | Position/status | Senior Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.54 | 547.914 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Vivienne Cox | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.54 | 434.553 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms Lynn Elsenhans | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $41.14 | 1,202.621 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Laurie Glimcher | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $41.14 | 1,336.245 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Jesse Goodman | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $41.14 | 403.177 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms Judy Lewent | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $41.14 | 449.255 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr Urs Rohner | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2019 to 30 June 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.54 | 547.914 |
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-07-24 | |||
f) | Place of the transaction
| n/a |
Related Shares:
Glaxosmithkline